CSP Exam Prep Course: Primary Biliary Cholangitis (PBC)

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/15

flashcard set

Earn XP

Description and Tags

Vocabulary review flashcards covering pathophysiology, diagnostic tests, and pharmacological therapies for Primary Biliary Cholangitis from the NASP 2025 CSP Exam Prep Course.

16 Terms

1
New cards

Primary Biliary Cholangitis (PBC)

An autoimmune disorder characterized by the gradual destruction of intrahepatic bile ducts, resulting in periportal inflammation, cholestasis, and potential progression to cirrhosis and portal hypertension.

2
New cards

Sicca Syndrome

An autoimmune condition presenting with dry eyes and dry mouth that frequently co-occurs with primary biliary cholangitis and adversely affects patient health-related quality of life.

3
New cards

Alkaline Phosphatase (ALP)

A key diagnostic and prognostic biomarker in PBC whose consistent elevation correlates with cholestasis, bile duct destruction, and increased risk of disease progression.

4
New cards

Anti-Mitochondrial Antibodies (AMAs)

Highly reliable diagnostic autoimmune antibodies that almost never occur in individuals without primary biliary cholangitis, even in the presence of other liver disorders.

5
New cards

Ursodeoxycholic Acid (UDCA)

The standard-of-care, first-line FDA-approved hydrophilic bile salt for PBC; it stabilizes hepatocyte membranes against toxic bile salts, inhibits apoptosis and fibrosis, and delays histological progression to cirrhosis when dosed at 13–15 mg/kg13\text{--}15\,\text{mg/kg} daily.

6
New cards

UDCA Biochemical Response Goal

A therapeutic target evaluated after 66 to 1212 months of ursodeoxycholic acid therapy defined as an ALP level <1.67×ULN< 1.67 \times \text{ULN} along with normal bilirubin.

7
New cards

Obeticholic Acid (OCA)

A farnesoid X receptor agonist approved for patients who do not tolerate or fail to respond to UDCA; reduces ALP, GGT, and transaminases through antifibrotic and choleretic properties but does not improve survival or disease-related symptoms.

8
New cards

Livdelzi (seladelpar)

A peroxisome proliferator-activated receptor (PPAR)-delta agonist indicated as monotherapy or with UDCA for PBC, administered at an oral dosage of 10 mg10\,\text{mg} once daily with or without food.

9
New cards

Iqirvo (elafibranor)

A dual peroxisome proliferator-activated receptor (PPAR) agonist and weak CYP3A4 inducer indicated for PBC at a dosage of 80 mg80\,\text{mg} orally once daily with or without food.

10
New cards

Livdelzi Contraindicated/Avoided Concomitant Medications

Concomitant use is specifically avoided with Organic Anion Transporter 3 (OAT3) inhibitors and strong CYP2C9 inhibitors.

11
New cards

Elafibranor Contraceptive Advisory

Because elafibranor is a weak CYP3A4 inducer that reduces the reliability of hormonal contraceptives, females of reproductive potential must switch to effective non-hormonal contraception or add a barrier method during therapy and for at least 33 weeks after the final dose.

12
New cards

Bile Acid Sequestrant Dosing Separation

UDCA must be separated by ≥1 hr\ge 1\,\text{hr} before or ≥4 hrs\ge 4\,\text{hrs} after bile-acid sequestrants; Livdelzi and Iqirvo must be administered at least 4 hours4\,\text{hours} before or 4 hours4\,\text{hours} after a bile acid sequestrant.

13
New cards

FibroScan

A specialized imaging test utilized in primary biliary cholangitis to noninvasively detect and quantify scarring (fibrosis) of the liver.

14
New cards

Magnetic Resonance Elastography (MRE)

An advanced imaging technique used to evaluate liver stiffness and detect liver hardening that may signal the development of cirrhosis.

15
New cards

Magnetic Resonance Cholangiopancreatography (MRCP)

A specialized magnetic resonance imaging examination designed to produce detailed structural images of the internal organs and biliary duct system.

16
New cards

Ascites Management in PBC

Interventions for abdominal fluid accumulation secondary to portal hypertension; mild cases require dietary sodium restriction, whereas severe cases require diuretics or paracentesis.